Pharmacotherapy for Dravet Syndrome

Area of Science:

• Neurology
• Genetics
• Pediatric Epilepsy

Background:

• Dravet syndrome (DS) is a severe, intractable pediatric epilepsy syndrome.
• It typically begins in early childhood with febrile status epilepticus and progresses to multifocal epilepsy and encephalopathy.
• Most cases are associated with mutations in the SCN1A gene.

Purpose of the Study:

• To review current and emerging treatments for Dravet syndrome.
• To emphasize pharmacotherapy strategies for seizure control and management of non-epileptic manifestations.
• To highlight contraindications and understudied treatment modalities.

Main Methods:

• Review of existing literature on Dravet syndrome treatments.
• Analysis of pharmacologic agents, including first-line and adjunctive therapies.
• Discussion of non-pharmacologic interventions and management of associated conditions.

Main Results:

• Epilepsy in DS is often medically refractory, necessitating polytherapy.
• Valproate and clobazam are first-line agents; topiramate, levetiracetam, stiripentol, and ketogenic diet show supportive data.
• Fenfluramine is a promising therapy; sodium channel blockers (carbamazepine, lamotrigine) are generally contraindicated.
• Non-epileptic manifestations like ADHD require pharmacologic management.
• Despite a high mortality rate, careful management improves clinical outcomes.

Conclusions:

• Pharmacotherapy is central to managing Dravet syndrome seizures and associated symptoms.
• Individualized treatment plans are crucial, considering refractory epilepsy and potential side effects.
• Further research into non-pharmacologic therapies and novel agents like fenfluramine is warranted.